Coronavirus Update: Brii Files US EUA For Antibody Combo
Plus, Wider Japan Ronapreve Use Sought
Executive Summary
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
You may also be interested in...
Coronavirus Update: Paxlovid Moves Towards EU Approval, Moderna Targets Omicron
Pfizer gets European Commission approval for Paxlovid after a positive CHMP opinion, while Moderna started a Phase II study of its Omicron-specific vaccine candidate. Meanwhile, China's Junshi enters into a new oral antiviral collaboration while Daiichi Sankyo investigates its mRNA vaccine contender as a booster shot.
China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.